This event-driven superiority trial randomised 9,650 adults with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease to oral semaglutide 14 mg or placebo
A research team led by Arun Sanyal, M.D., director of Virginia Commonwealth Universitys Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, and Philip Newsome, Ph.D., of Kings College London, has been involved in the clinical trials exploring the potential of semaglutide the GLP-1 receptor agonist used for Wegovy and Ozempic to treat people with this type of liver disease
Oxidative stress and inflammation are tightly linked to virtually every degenerative condition associated with aging: from atherosclerosis and cancer to neurodegeneration and sarcopenia
Epithalon is supplied as a white lyophilized powder at 10mg per vial, exceeding 98% purity by HPLC analysis
That is where this story becomes more interesting than a standard drug launch
It's always great to sit down and talk to you
